Literature DB >> 22138256

Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice.

Didier Bouhassira1, Olivier Chassany, Jacques Gaillat, Thomas Hanslik, Odile Launay, Claude Mann, Christian Rabaud, Olivier Rogeaux, Christophe Strady.   

Abstract

Understanding the effect of herpes zoster and zoster-related pain should inform care to improve health-related quality of life in elderly patients. A 12-month, longitudinal, prospective, multicenter observational study conducted in primary care in France enrolled patients aged ≥ 50 years with acute eruptive herpes zoster. Patient-reported zoster-related pain was assessed by validated questionnaires (Douleur Neuropathique en 4 Questions [DN4], Zoster Brief Pain Inventory [ZBPI], and Neuropathic Pain Symptom Inventory [NPSI]) on days 0 and 15, and at months 1, 3, 6, 9, and 12. Health-related quality of life was assessed by the 12-item short-form health survey (SF-12) and the Hospital Anxiety and Depression scale on day 0 and at months 3, 6, and 12. Of 1358 patients included, 1032 completed follow-up. Mean ± standard deviation age was 67.7 ± 10.7 (range, 50-95) years; 62.2% were women. Most patients (94.1%) were prescribed antiviral drugs. The prevalence of zoster-related pain on day 0 and at months 3, 6, 9, and 12 was 79.6%, 11.6%, 8.5%, 7.4%, and 6.0%, respectively. Patients with persistent pain had lower scores on the physical and mental component summaries of the SF-12 and the ZBPI interference score than those without pain. By logistic regression analysis, main predictive factors on day 0 for postherpetic neuralgia at month 3 were age, male sex, ZBPI interference score, Physical Component Summary score of the SF-12, and neuropathic quality of pain (DN4 score ≥ 4). Despite early diagnosis and treatment with antiviral agents, many patients with herpes zoster experience persistent pain and marked long-term reduction in health-related quality of life.
Copyright © 2011 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22138256     DOI: 10.1016/j.pain.2011.10.026

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  46 in total

Review 1.  Epidemiology of neuropathic pain and its impact on quality of life.

Authors:  Blair H Smith; Nicola Torrance
Journal:  Curr Pain Headache Rep       Date:  2012-06

Review 2.  Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective.

Authors:  Robert W Johnson; Marie-José Alvarez-Pasquin; Marc Bijl; Elisabetta Franco; Jacques Gaillat; João G Clara; Marc Labetoulle; Jean-Pierre Michel; Luigi Naldi; Luis S Sanmarti; Thomas Weinke
Journal:  Ther Adv Vaccines       Date:  2015-07

Review 3.  Topical capsaicin (high concentration) for chronic neuropathic pain in adults.

Authors:  Sheena Derry; Andrew Sc Rice; Peter Cole; Toni Tan; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-01-13

4.  Sciatic nerve transection modulates oxidative parameters in spinal and supraspinal regions.

Authors:  Taína Scheid; Lidiane Dal Bosco; Renata P Guedes; Maria Amália Pavanato; Adriane Belló-Klein; Wania A Partata
Journal:  Neurochem Res       Date:  2013-02-20       Impact factor: 3.996

Review 5.  Vaccination in the elderly: what can be recommended?

Authors:  Pierre-Olivier Lang; Richard Aspinall
Journal:  Drugs Aging       Date:  2014-08       Impact factor: 3.923

6.  Effectiveness of real-time PCR for diagnosis and prognosis of varicella-zoster virus keratitis.

Authors:  Kodai Inata; Dai Miyazaki; Ryu Uotani; Daisuke Shimizu; Atsuko Miyake; Yumiko Shimizu; Yoshitsugu Inoue
Journal:  Jpn J Ophthalmol       Date:  2018-06-11       Impact factor: 2.447

7.  Cost-effectiveness of a herpes zoster vaccination program among the French elderly people.

Authors:  Emmanuel Belchior; Daniel Lévy-Bruhl; Yann Le Strat; Magid Herida
Journal:  Hum Vaccin Immunother       Date:  2016-08-02       Impact factor: 3.452

8.  Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis.

Authors:  Phuc Le; Michael B Rothberg
Journal:  J Gen Intern Med       Date:  2016-10-14       Impact factor: 5.128

9.  Consistence and discrepancy of neuropathic pain screening tools DN4 and ID-Pain.

Authors:  L Padua; C Briani; A Truini; I Aprile; D Bouhassirà; G Cruccu; S Jann; E Nobile-Orazio; C Pazzaglia; A Morini; M Mondelli; P Ciaramitaro; G Cavaletti; D Cocito; R Fazio; L Santoro; F Galeotti; M Carpo; R Plasmati; L Benedetti; A Schenone
Journal:  Neurol Sci       Date:  2012-03-21       Impact factor: 3.307

10.  Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.

Authors:  Phuc Le; Michael B Rothberg
Journal:  JAMA Intern Med       Date:  2018-02-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.